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Abstract 
Stable overexpression of endothelial nitric oxide synthase (NOS-3) in HepG2 cells 
(4TO-NOS) leads to increased nitro-oxidative stress and upregulation of the cell death 
mediators p53 and Fas. Thus, NOS-3 overexpression has been suggested as a useful 
antiproliferative mechanism in hepatocarcinoma cells. We aimed to identify the 
underlying mechanism of cell death induced by NOS-3 overexpression at basal 
conditions and with anti-Fas treatment. The intracellular localization of NOS-3, the 
nitro-oxidative stress and the mitochondrial activity were analysed. In addition, the 
protein expression profile in 4TO-NOS was screened for differentially expressed 
proteins potentially involved in the induction of apoptosis. NOS-3 localization in the 
mitochondrial outer membrane was not associated with changes in the respiratory 
cellular capacity, but was related to the mitochondrial biogenesis increase and with a 
higher protein expression of mitochondrial complex IV. Nitro-oxidative stress and cell 
death in NOS-3 overexpressing cells occurred with the expression increase of pro-
apoptotic genes and a higher expression/activity of the enzymes adrenodoxin reductase 
mitochondrial (AR) and cathepsin D (CatD). CatD overexpression in 4TO-NOS was 
related to the apoptosis induction independently of its catalytic activity. In addition, 
CatD activity inhibition by pepstatin A was not effective in blocking apoptosis induced 
by anti-Fas. In summary, NOS-3 overexpression resulted in an increased sensitivity to 
anti-Fas induced cell death, independently of AR expression and CatD activity. 
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DCFDA: 2,7-dichlorofluorescein-diacetate, DHE: dihydroethidium, mtDNA: 
mitochondrial DNA, cyt c: cytochrome c, IEF: isoelectrofocusing, 2-DE: two 
dimensional electrophoresis, SOD: superoxide dismutase, GPX: glutathione peroxidase, 
GSS: glutathione synthetase, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, 
PRDX: thioredoxin-dependent peroxide reductase, AR: adrenodoxin reductase or 
NADPH:adrenodoxin oxidoreductase mitochondrial, CatD: cathepsin D, HSP60: heat 
shock protein 60, PDI: protein disulfide isomerase, OXPHOS: oxidative 
phosphorylation. 
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1. Introduction 
Nitric oxide (NO) is a lipophilic, highly diffusible and short-lived physiological 
messenger, which regulates a variety of important biological processes such as 
vasodilation, respiration, cell migration, immune response and apoptosis. NO is 
produced within cells by nitric oxide synthases (NOS) using L-arginine as substrate, 
resulting in the formation of L-citrulline and the end products of NO oxidation, nitrite 
and nitrate [1]. There are three isoforms of NOS: neuronal (nNOS or NOS-1), inducible 
(iNOS or NOS-2) and endothelial (eNOS or NOS-3). All of them share similar 
structures and catalytic modes, but they show different mechanisms regulating their 
expression and activities [2]. In addition, a new NOS isoform was found in the 
mitochondria, but whether it corresponds to one of the known isoforms is a matter of 
discussion [3-5]. 
The expression of NOS isoforms, including those constitutively expressed, may be 
triggered by different stimuli and in a tissue-dependent manner. In the liver, NO can be 
synthesized by the activity of any of the NOS isoforms [6], but its role is an issue of 
debate. NO is a mediator of liver injury, but also able to protect against hepatocellular 
damage, depending on factors such as its concentration or the generating source. 
Furthermore, the liver expression of NOS isoforms and the NO production have been 
related to cancer development through pro-/anti-apoptotic activities. NOS-3 may be 
overexpressed in different types of tumors, and may modulate several cancer-related 
events such as angiogenesis, apoptosis, cell cycle, invasion or metastasis [1]. By 
contrast, NOS-3 activation has also been associated with the inhibition of growth and 
proliferation of hepatoma cells [7]. The molecular mechanism by which NO exerts this 
antitumoral activity has been related to the inhibition of the mitochondrial electron 
transport chain and to the induction of nitro-oxidative stress [8,9]. 
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We have previously reported that the NOS-3 overexpression in a hepatocarcinoma cell 
line is related to apoptosis induced by nitro-oxidative stress and up-regulation of p53 
oncoprotein and cell death receptor Fas (or CD95) [10]. Furthermore, the 
pharmacological modulation of the Fas/Fas ligand (FasL or CD95L) signalling 
machinery has been suggested as an useful therapeutic strategy, but caution is warranted 
because administration of agonistic Fas-specific antibodies [11] or FasL [12] cause 
extensive hepatocyte apoptosis and fatal hepatitis in mice. The increase of Fas-mediated 
apoptosis may be a promising anticancer therapy in liver disease [10]. In addition, NO-
donor molecules have shown antitumoral properties in vitro and in vivo [10,13]. 
In this study, we aimed to investigate the mechanism by which the stable overexpression 
of NOS-3 induces cell death in the hepatocarcinoma cell line HepG2, both in basal 
conditions and with anti-Fas treatment. 
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2. Material and methods 
2.1. NOS-3 overexpression and culture conditions 
The cell line with stable overexpression of NOS-3 (4TO-NOS) and its corresponding 
control cell line (4TO) were obtained and maintained as described elsewhere [14,10]. 
The cell culture medium was supplemented with 2.5mM L-arginine to ensure the NOS 
substrate availability. Cells were seeded to a confluence of 150,000 cells/cm
2
, and the 
measurements were carried out after 48h. The cell death-inducing agent anti-Fas (Anti-
Human Fas or CD95; 0.5μg/ml. MBL, Nagoya, Japan) was administered 48h after 
seeding the cells. Cells were collected 2h later. The cell-permeable NOS inhibitor N
ω
-
Nitro-L-arginine methyl ester hydrochloride (L-NAME; 5mM. Sigma-Aldrich, 
Missouri, USA) and the cathepsin D inhibitor pepstatin A (20μM or 50μM; Santa Cruz 
Biotechnology, California, USA) were added to the culture medium 24h after seeding 
the cells. 
2.2. NOS-3 subcellular distribution 
For western blot localization analysis, the mitochondrial fraction was isolated by 
ultracentrifugation in a discontinuous sucrose gradient performed with 0.8, 1.0, 1.2, 1.4 
and 1.6M sucrose concentrations in 2mM HEPES buffer pH 7.4. This method allows for 
an efficient purification of the mitochondrial fraction and minor contamination with 
endoplasmic reticulum [15]. Then, mitochondria were subjected to enzymatic digestion 
with trypsin (6 or 20µg /100µg protein) or proteinase-K (10 or 40µg /100µg protein). 
10µg of protein were separated by SDS-PAGE, electroblotted onto nitrocellulose 
membrane, and sequentially probed with specific antibodies against MTCO2 (a protein 
from the inner mitochondrial membrane) (Life Technologies), translocase of outer 
mitochondrial membrane 40 homolog (TOM40) and NOS-3 (Santa Cruz 
Biotechnology). The cellular localization of the NOS-3 protein was additionally 
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assessed by using a confocal microscope (LSM 5 Exciter) and a confocal imaging 
system (ZEN 2008, Carl Zeiss, Jena, Germany). Cells were fixed and incubated with the 
primary antibodies anti-NOS-3 (Santa Cruz Biotechnology) and anti-MTCO2 (Abcam, 
Cambridge, UK). Secondary conjugated antibodies were Alexa Fluor 488 and 594 (Life 
Technologies, California, USA). The specificity of the immunoreactivity was verified 
by incubating cells without the primary antibodies. ImageJ software was used to assess 
the mitochondrial localization of NOS-3 (http://imagej.nih.gov/ij/). 
2.3. Oxygen Consumption 
O2 consumption determinations in intact cells or in digitonin-permeabilized cells were 
carried out in an oxygraph with a Clark electrode (Hansatech Instruments, Norfolk, UK) 
[16]. Briefly, 5 x 10
6
 cells were trypsinized, counted and resuspended in culture 
medium or respiration buffer (10mM MgCl2, 250mM Sucrose, 20mM HEPES pH 7.4, 
1mM ADP, 2mM KH2PO4), respectively. Oxygen consumption was measured at 37º C 
with stirring. 6.25µM FCCP was used to uncouple respiration in intact cells. For 
polarographic measurements, cells were permeabilized with 1% digitonin (1.2µl / 10
6
 
cells) and the oxygen consumption was recorded after the addition of substrates and 
inhibitors for Complex I (5mM Glutamate plus Malate, 2µM Rotenone), Complex II + 
III (5mM Succinate plus Gliceraldehide-3-P, 0.1µM Antimycin A) and Complex IV 
(1.2mM TMPD, 6mM KCN). 
2.4. Mitochondrial membrane potential 
The mitochondrial membrane potential (MMP) was monitored by using the potential-
sensitive fluorescent probe tetramethyl-rhodamine methyl ester (TMR) (Life 
Technologies). Briefly, cells were washed with PBS and further incubated with 10μM 
TMR for 20min. The registration of the measurement was started with the addition of 
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5mM glucose. The fluorescence emitted by TMR (ex=550nm, em=570nm) was 
detected in situ using a GENios Microplate Reader (TECAN, Männedorf, Switzerland). 
2.5. Quantitative analysis of protein nitration 
The quantification of protein nitration as a measurement of reactive nitrogen species 
(RNS) was determined in the mitochondrial fraction by western blot. The post-
translational modification 3-nitrotyrosine was used for this purpose. The protein 
samples were separated by SDS-PAGE in non-reducing conditions, transferred to 
nitrocellulose membrane, and probed with an anti-3-nitrotyrosine primary antibody 
(Sigma-Aldrich) [10]. The data from the densitometry analysis of the 55kDa protein 
band were normalized to a total protein value of 10μg. 
2.6. Nitric oxide production 
NO production was determined by the Griess reaction as we previously described [14]. 
NO-related end products nitrates and nitrites were quantified in the cell culture medium 
2h after anti-Fas administration. Nitrite concentrations were accurately determined by a 
nitrite calibration curve. 
2.7. Determination of mitochondrial reactive oxygen species 
Cellular reactive oxygen species (ROS) were detected by using the fluorescent probes 
2,7-dichlorofluorescein-diacetate (DCFDA) and dihydroethidium (DHE) (Life 
Technologies). The cells were washed and then incubated with 10μM DCFDA or 5μM 
DHE for 20min or 10min, respectively. Measurements were initiated by the addition of 
5mM glucose. The fluorescence emitted by DHE (ex= 510nm, em= 590nm) and 
DCFDA (ex= 500nm, em= 520nm) was assessed in situ using a microplate reader. 
DHE was not used with L-NAME because the NOS inhibitor appeared to interact with 
the probe (data not shown). 
9 
 
2.8. Gene expression analysis and mitochondrial DNA copy number 
quantification 
The expression analysis of the antioxidant and pro-apoptotic genes was determined by 
RT-qPCR using a LightCycler 480 System (Roche, Basel, Switzerland) and the One-
Step QuantiTect SYBR-Green Kit (Qiagen, Limburg, Netherlands). Total cellular RNA 
was extracted by using TRIsure reagent (Bioline, London, UK), treated with RNAse-
Free DNase (Promega, Wisconsin, USA), and used as template for mRNA amplification 
with specific human oligodeoxynucleotides designed by Primer3 software (v.0.4.0). The 
expression of ribosomal protein L13A (RPL13A) was used as a reference gene. The 
primer sequences and positions into the cDNA are summarized in Table 1. The RNA 
concentration and its integrity were confirmed by standard procedures. The PCR 
reaction was performed in duplicate, by adjusting the annealing temperature to 60ºC and 
in a final volume of 10µl. 
The mitochondrial DNA (mtDNA) quantification was also performed by RT-qPCR with 
the ThermOne
TM
 RT-PCR Premix (RBC, Taipei, Taiwan). The total cellular DNA 
extracted using standard procedures was used as template and was amplified with 
specific oligodeoxynucleotides for MTCO2 and succinate dehydrogenase subunit A 
(SDHA), as previously reported [17]. MtDNA copy number per cell was calculated 
using SDHA amplification as a reference for nuclear DNA content. 
2.9. Mitochondrial protein expression analysis 
Expression analysis for mitochondrial proteins from respiratory complexes was assessed 
by western blot. 40µg from total cellular proteins were separated by SDS-PAGE, then 
transferred to nitrocellulose membrane, and finally probed with primary antibodies anti-
NDUFB6 (complex I), anti-SDHB (complex II), anti-UQCRC2 (complex III), and anti-
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MTCO2 (complex IV), respectively (Life Technologies). The densitometry analysis of 
the lines after Ponceau S staining was used as protein-loading control. 
2.10. Cell death analysis 
Cell death was assessed in cell lysates by the release of cytochrome c (cyt c) from the 
mitochondria, and by the caspase-9 and caspase-3 enzyme activity. The cytoplasmic cyt 
c release was determined by western blot analysis by using the anti-cyt c primary 
antibody (Santa Cruz Biotechnology), and anti--actin (Abcam) as protein-loading 
control. Caspase-9/-3 activities were spectrophotometrically measured as previously 
reported [10].  
2.11. Protein expression profiling by two dimensional electrophoresis 
Protein samples were obtained in 20mM Tris-HCl pH 7.6, 0.5M Sucrose, 0.15M KCl, 
10µg/ml leupeptin, 2µg/ml aprotinin, 10mg/ml PMSF and 20mM DTT supplemented 
with the commercial Mini EDTA-free protease inhibitor cocktail (Roche). Proteins were 
quantified by the Bradford assay and 300μg of total cellular proteins were used in each 
isoelectrofocusing (IEF) strip (18cm ReadyStrip
TM
 IPGStrips pH 3-10 nonlinear). The 
IEF program and the two dimensional electrophoresis (2-DE) conditions were 
performed as detailed in [14]. Gels from 2-DE were stained with SYPRO Ruby, and 
further digitalized with the FX ProPlus Multiimager. The analysis of the differential 
intensity spot and the spot volume, normalized by the total density in gels, was 
quantified by using the PDQuest software (v.8.0.1) (Bio-Rad Laboratories, California, 
USA). Protein samples from four independent experiments were run in triplicate. 
2.12. Identification of differentially expressed proteins 
Differentially expressed protein spots were excised from the preparative 2-D gel by 
using a ProPic workstation (Genomic Solutions Inc., Michigan, USA), digested with 
trypsin, and subjected to MALDI-TOF analysis in the UCO-SCAI proteomics facility 
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(Córdoba, Spain. Carlos III Networked Proteomics Platform, ProteoRed-ISCIII) [14]. 
The confirmation of the results was performed by western blot, using 5μg of total 
cellular proteins and the primary antibodies anti-HSP60, anti-PDI, anti-ADX Reductase, 
and anti-PRDX3 (Santa Cruz Biotechnology). 
2.13. Cathepsin D Activity Assay 
Cathepsin D activity was measured in cell lysates with the use of a commercial assay kit 
(Abcam) following the manufacturer recommendations. Data were normalised by the 
cell number, which was assessed immediately before the enzyme activity measurement. 
2.14. Statistical analysis 
Results were expressed as mean ± standard error. Data were compared using the non-
parametric method Kruskal-Wallis and the Mann-Whitney’s U test, searching for 
differences between groups (n<30). All tests and calculations were done with the 
statistical package SPSS 15.0 for Windows (IBM). Statistical difference was set at 
p≤0.05. * Indicates statistically significant differences between cell lines for a same 
condition. # Indicates statistically significant differences between conditions (anti-Fas 
or L-NAME vs. basal; +L-NAME vs. anti-Fas) for a same cell line. 
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3. Results 
3.1. NOS-3 localizes in the mitochondrion outer membrane 
The western blot analysis of NOS-3 in different subcellular fractions showed an 
expression of the protein in membranes, cytoplasm and mitochondria from 4TO-NOS 
cells (Fig. 1A). In addition, enzymatic treatment of intact mitochondria with trypsin and 
proteinase-K efficiently removed NOS-3 and TOM40 from mitochondria, but not 
MTCOII since the proteases cannot access inner membrane proteins (Fig. 1B). The 
confocal immunofluorescence study showed that NOS-3 was primarily localized in the 
plasma membrane and in the cellular cytoplasm of the NOS-3-overexpressing cells (Fig. 
1C). The mitochondrial localization of NOS-3 was not confirmed by this approach.  
In order to assess the effect of anti-Fas on the subcellular distribution of NOS-3 and cell 
death susceptibility, we studied the mitochondrial localization of the protein in the 
presence of the apoptosis inducer. As shown in figure 1A, anti-Fas had a trend to an 
increased NOS-3 expression in 4TO-NOS, which coincided with a reduced localization 
of the protein in the mitochondrial fraction (0.24 vs. 0.06, p=0.021). 
3.2. Stable overexpression of NOS-3 does not affect the cell respiratory capacity 
In order to evaluate the role of NOS-3 overexpression on cellular respiration, we 
analysed oxygen consumption associated with mitochondrial complexes I (CI), II+III 
(CII+III) and IV (CIV) in the 4TO-NOS cell line. As shown in figure 2, NOS-3 
overexpression was related to a subtle increase in respiratory activity of CII+III (119%, 
p=0.024), without affecting oxygen consumption dependent of CI and CIV (Fig. 2A). 
This resulted in a non-significant increase of the endogenous cellular respiratory 
capacity (Fig. 2B) and in a higher MMP (129%, p=0.004) (Fig. 2C). When the cell-
permeable NOS inhibitor L-NAME was added to the cell culture medium, an increase 
in oxygen consumption dependent on CI and CII+III, in both 4TO (166% p=0.014 and 
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118% p=0.033, respectively) and 4TO-NOS cell line (154% p=0.025 and 138% 
p=0.052, respectively) was observed (Fig. 2A). The induction of apoptosis by anti-Fas 
led to a statistically significant decrease in oxygen consumption mostly due to 30% loss 
of CI activity (p=0.011), and reduced the endogenous respiratory capacity (5.4 vs. 6.3, 
p=0.050) and maximum respiratory capacity (10.1 vs. 12.9, p=0.050) in 4TO-NOS 
when compared to 4TO cells (Fig. 2A and 2B). The simultaneous administration of anti-
Fas and L-NAME had a similar effect on oxygen consumption as that caused by the sole 
addition of L-NAME on 4TO cells. By contrast, in 4TO-NOS, L-NAME inhibited the 
effect of anti-Fas on the mitochondrial CI (p=0.053). The oxygen consumption increase 
induced by L-NAME in the presence of anti-FAS was paralleled by MMP increase in 
the two cell lines. 
3.3. Nitro-oxidative stress and mtDNA copy number are enhanced in 4TO-NOS 
The mitochondrial localization of NOS-3 in 4TO-NOS cells was associated with 
increased levels of tyrosine nitration of mitochondrial proteins (85.48 vs. 35.81, 
p=0.050), which translates the production of RNS (Fig. 3A). In addition, NOS-3 
overexpressing cells accumulated a higher concentration of nitric oxide end products in 
the cell culture medium (Fig. 3B), and showed a general ROS production increase 
(168%, p<0.001 for DCF; 149%, p=0.048 for DHE) (Fig. 3C) and an up-regulation of 
antioxidant genes encoding for proteins superoxide dismutase (SOD)-1 (154%, 
p=0.032), SOD-2 (210%, p=0.019), catalase (149%, p=0.021), glutathione peroxidase 
(GPX)-1 (235%, p=0.032), GPX-4 (155%, p=0.032), and glutathione synthetase (GSS) 
(167%, p=0.034) (Fig. 3D). The administration of L-NAME did not reduce oxidative 
stress in 4TO-NOS (Fig. 3C), but caused a reduction of mitochondrial protein nitration 
(Fig. 3A), and a lower accumulation of nitrates and nitrites in the cell culture medium 
(Fig. 3B), which balanced the observed differences between 4TO-NOS and the control 
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cell line 4TO. The nitro-oxidative stress related to NOS-3 overexpression was 
associated with an increased mtDNA copy number (148%, p<0.001) (Fig. 3E), and with 
a higher protein expression of mitochondrial CIV (163%, p=0.019) (Fig. 3F).  
Anti-Fas led to the accumulation of nitrates and nitrites in the cell culture medium of 
4TO-NOS cells (1.25 vs. 4.12, p=0.034) (Fig. 3B). In addition, anti-Fas induced the 
antioxidant gene expression in 4TO cells, but it had no additional effect on gene 
expression and oxidative stress in the 4TO-NOS cell line (Fig. 3C and 3D). 
3.4. NOS-3 overexpression increases susceptibility to anti-Fas-induced cell death 
As shown in figure 4A, NOS-3 overexpression was associated with an increased 
expression of pro-apoptotic genes Bax (164%, p=0.003), Bik (354%, p=0.002) and 
Apaf-1 (168%, p=0.002) at basal conditions. This coincided with a higher localization 
of cyt c in the cytoplasm (168%, p=0.019), and the increase of caspase-9 (124%, 
p=0.047) and caspase-3 (166%, p=0.011) associated activities (Fig. 4B and 4C). The 
administration of anti-Fas stimulated Bik expression in 4TO (146%, p=0.010) and 4TO-
NOS cells (563%, p=0.007), without affecting Bax or Apaf-1. In addition, anti-Fas 
caused an increase in the caspase-3 activity in both cell lines (153% and 318%, 
respectively; p<0.050), as well as a higher caspase-9 activity only in 4TO-NOS (229%, 
p=0.034). There were no significant differences in the release of cyt c after incubation 
with anti-Fas. 
3.5. Comparative proteomic profile of the 4TO-NOS cell line 
The proteomic profile of 4TO-NOS cells was analysed and further compared to that of 
the control cell line 4TO, searching for differentially expressed proteins that could be 
involved in the process of ROS production and cell death observed at basal condition. 
The quantitative analysis of the gels yielded 110 spots with significantly altered 
expression. 56 of these spots were identified by mass spectrometry as 42 different 
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proteins. The location of these spots in the master gel is shown in figure 5A. 
Supplementary figure 1 shows a representative 2-D gel for each condition. 
Differentially expressed proteins have been classified according to their main biological 
functions (Table 2). Differences in proteins involved in metabolism (11), cytoskeleton 
(2), RNA processing (5), protein processing (8), protein degradation (6), and redox 
homeostasis (10) were found. NOS-3 overexpression mainly affected the expression of 
proteins involved in metabolism (8) and redox system (8). Among the metabolic 
proteins, three were up-regulated proteins (+) involved in the β-oxidation and glycolysis 
processes: medium and short-chain-specific acyl-CoA dehydrogenases (+5.4/+2.8, 
respectively), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; +2.3). In the 
second largest group of proteins deregulated by NOS-3 overexpression, we found over-
expression of proteins in both the cell anti-oxidant system and the pro-oxidant system: 
thioredoxin-dependent peroxide reductase mitochondrial (PRDX3; +3.2), 
peroxiredoxin-2 (PRDX2; +2.1), superoxide dismutase [Mn] mitochondrial (SOD2; 
+3.2), and NADPH:adrenodoxin oxidoreductase mitochondrial (ADX reductase or AR; 
+3.7). Cathepsin D (CatD) was identified in two different spots as a protease 
upregulated by NOS-3 overexpression (+2.3 and +1.9), and in a third additional spot 
that was only detected in 4TO-NOS cells. 
In the presence of anti-Fas, the cell lines 4TO and 4TO-NOS showed differences in the 
protein expression profile as a consequence of NOS-3 overexpression. The differentially 
expressed proteins were mainly involved in protein processing (6), protein degradation 
(6) and redox homeostasis (5). The apoptosis inductor did not modify the expression 
pattern of CatD in 4TO-NOS. 
In order to verify 2-D PAGE/MS results, we randomly chose four proteins from those 
previously identified by MS, and confirmed their relative expression deregulation by 
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western blot analysis. These proteins were heat shock protein 60 (HSP60), protein 
disulfide isomerase (PDI), PRDX3, and AR (Fig. 5B). 
3.6. Cathepsin D expression, but not its activity, is associated with cell death 
Next, we investigated the role of CatD in NOS-3 overexpressing cells. As shown in 
figure 6, the overexpression of CatD in 4TO-NOS cells was accompanied by the 
increase of its enzymatic activity (176%, p=0.020) (Fig. 6A). The inhibition of CatD 
activity by 20μM pepstatin A (Fig. 6B) had no effect on cell growth (Fig. 6C) but it was 
associated with the activity increase of caspase-3 (1.23 fold, p=0.050) and caspase-9 
(1.22 fold, p=0.037) in 4TO-NOS when compared to basal condition (Fig. 6D and 6E). 
At 50μM, pepstatin A caused a significant increase in cell doubling time in the 4TO-
NOS cell line (66.2 vs. 47.5, p=0.021) (Fig. 6F), which was paralleled by a higher 
caspase-3 activity (1.73 fold increase, p=0.047) (Fig. 6G). The addition of anti-Fas to 
the cell culture medium did not affect CatD activity in the cell lines 4TO or 4TO-NOS 
(Fig. 6A). By contrast, the simultaneous administration of anti-Fas and pepstatin A 
resulted in the activity increase of caspase-3 (p=0.050) in the cell line 4TO-NOS when 
compared to the condition of anti-Fas addition (Fig. 6D). 
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4. Discussion 
We have previously shown that stable NOS-3 overexpression induces the oncoprotein 
p53 and the cell death receptor Fas, in HepG2 cells as well as in tumors subcutaneously 
developed in a xenograft mouse model [10]. Indeed NOS-3 up-regulation has been 
suggested as a candidate antiproliferative mechanism in hepatocarcinoma cells. In the 
present study, we have investigated the mechanisms involved in cell death promoted by 
NOS-3 overexpression. In addition, we have explored the susceptibility to anti-Fas-
induced cell death in the 4TO-NOS cell line. Figure 7 summarizes in a representative 
scheme the main findings of this study about cell death mechanisms induced by NOS-3 
overexpression in 4TO-NOS. 
As NOS-3 is expressed in mitochondria [3], and it is well known the key role of this 
organelle in apoptotic cell-death, we analysed the expression pattern of the protein in 
4TO-NOS cells. We found that NOS-3 is mainly localized in the plasma membrane and 
cytoplasm, which agrees with earlier studies in which NOS-3 was present in the Golgi 
complex and in cell-cell contacts of confluent cells [18]. In addition, we observed that 
NOS-3 colocalized with mitochondrial proteins, and that NOS-3 was cleaved from the 
mitochondria by a protease treatment, suggesting its association with the outer 
mitochondrial membrane. This was consistent with the high levels of tyrosine nitration 
of mitochondrial proteins observed in NOS-3 overexpressing cells. Due to the inhibitory 
effect that NO has on the oxidative phosphorylation (OXPHOS) system, its ability to 
diffuse through cell membranes, and the finding that NOS-3 is localized in the 
mitochondria, we next investigated the respiratory capacity of the 4TO-NOS cell line. 
Unexpectedly, NOS-3 overexpression did not cause any relevant effect on the 
mitochondrial respiration. Despite this, 4TO-NOS cells showed increased levels of 
oxidative stress that coincided with the expression increase of genes involved in ROS 
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detoxification and with a high mtDNA copy number, compared to the control cell line 
4TO. In this regard, previous studies have shown that mtDNA biogenesis may be 
regulated by oxidative stress under different conditions [19], and that NO is able to 
trigger mitochondrial biogenesis in culture cells [20]. The increase in mtDNA copy 
number was paralleled by a higher expression of the mtDNA-encoded protein MTCO2, 
which may be an attempt by 4TO-NOS cells to adapt to the conditions of NO 
overproduction.  
With the aim to link these previous observations to NOS-3 overexpression, we 
additionally used L-NAME. This commonly used NOS inhibitor effectively suppressed 
the effects of NOS-3 overexpression relating to the accumulation of NO end products 
and the nitration of mitochondrial proteins. However, L-NAME was not effective in 
suppressing oxidative stress induced by NOS-3 overexpression. Conversely, L-NAME 
caused an increased activity of the OXPHOS system, which is closely related to ROS 
production [21] and may be a consequence of the inhibitory effect of NO on the 
respiration [8]. Nevertheless, L-NAME caused a similar effect in both cell lines 4TO 
and 4TO-NOS, thus indicating that NOS-3 overexpression has not a relevant role in 
mitochondrial respiration. This result was confirmed when we measured cellular 
respiration in non-permeabilized cells. Thus, despite the inhibitory effect of NO in 
respiration, the apoptosis induction by NOS-3 overexpression did not occur through 
dysfunction of the OXPHOS system. 
We have previously shown that 4TO-NOS cell line has increased levels of p53 protein 
[10], which is an important cell cycle regulator able to initiate apoptosis in response to 
oxidative stress [22]. Indeed, p53 activity has been related to the expression regulation 
of several apoptotic genes [23]. In the present study, NOS-3 overexpression was 
associated with the expression increase of pro-apoptotic genes such as Bax, Bik and 
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Apaf-1, and with a consequent release of cyt c into the cytoplasm and the activity 
increase of caspase-9 and caspase-3. These results would explain the spontaneous 
apoptosis showed by 4TO-NOS at basal condition. In addition, NOS-3 overexpression 
was related to MMP increase, consistent with the induction of apoptosis through the 
mitochondrial membrane hyperpolarization. 
When we analysed the effect of anti-Fas in the 4TO-NOS cell line, we found that the 
apoptosis inductor caused a lower localization of NOS-3 in the mitochondria. This 
observation coincided with a decrease in the cellular content of nitrated mitochondrial 
proteins, but also with a non-relevant reduction in respiratory capacity and the complex 
I-dependent oxygen consumption. As expected, NOS-3 overexpressing cells showed 
increased susceptibility to anti-Fas-induced cell death, which was mediated by the 
activity increase of caspase-9 and caspase-3. By contrast, apoptosis induction in the 
control cell line 4TO was only related to the increase of caspase-3 activity. Therefore, 
while in the control cell line anti-Fas induced apoptosis through the extrinsic pathway, 
an additional activation of both the extrinsic and the mitochondrial apoptotic pathways 
was observed in 4TO-NOS, which was higher than that induced by NOS-3 
overexpression alone.  
In order to identify intermediates that could be involved in the process of cell death in 
4TO-NOS, we analysed the protein expression profile compared to the control cell line 
4TO. We identified proteins with different biological functions, whose differential 
expression is associated with the reduction of cell growth. Regarding the group of 
metabolic proteins, it should be noted that nitrosylation is a posttranslational 
modification by which NO can reversibly regulate β-oxidation [24] and glycolysis [25]. 
In particular, GAPDH activity may be regulated by nitrosylation, being its 
hyperactivation an adaptive pro-survival response under pro-oxidant conditions [26]. By 
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contrast, nitrosylated GAPDH is able to be transferred to the nucleus and to activate 
p53, leading to cell death [27]. In this regard, we have previously reported that NOS-3 
overexpression increases the profile of S-nitrosylated proteins [14], and induces p53 
expression in HepG2 [10], reducing cell survival. Adding anti-Fas to the cell culture 
induced GAPDH expression in the control cell line, thus abolishing the difference 
induced by NOS-3 overexpression. 
In the second largest group of identified proteins, we found over-expression of proteins 
involved in the cellular antioxidant system. This agreed with the gene expression profile 
of 4TO-NOS. Thus, the up-regulation of antioxidant enzymes through activation of the 
ROS-sensitive signalling pathway is well established. Peroxiredoxins are involved in 
the attenuation of the generation of reactive oxygen /nitrogen species and NO [28,29], 
and may be regulated by nitrosylation [30]. Moreover, we detected a significant increase 
of AR in the 4TO-NOS cell line. AR is a mitochondrial oxidoreductase that catalyses 
the oxidation of NADPH, acting as the first electron transfer protein of mitochondrial 
P450 systems. This system can work as a futile NADPH oxidase, oxidizing NADPH in 
absence of substrate, leaking electrons to O2 and generating ROS [31]. AR was 
particularly interesting because it participates in the p53-mediated apoptosis by 
oxidative stress [32]. Here, increase of AR expression induced by NOS-3 
overexpression coincided with ROS production, p53 accumulation [10], and apoptosis 
induction through the expression of pro-apoptotic genes that are regulated by p53. In 
agreement with the oxidative status of the cell lines, anti-Fas did not change the 
expression profile of AR in 4TO and 4TO-NOS.  
The protease CatD was identified in two up-regulated spots, as well as in a third 
additional spot only detected in 4TO-NOS, which probably belongs to a chemical 
modification of the protein. Indeed the posttranslational modification of CatD has been 
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implicated in tissue remodelling occurring after lactation [33]. In accordance with the 
protein expression analysis, the stable overexpression of NOS-3 increased the CatD 
activity in HepG2 cells. These results were also related to p53 expression [10,34] and 
agree with previous observations in which CatD participated in the apoptosis induction 
by NO [35]. Furthermore, it has been reported that the genetic and pharmacological 
inhibition of CatD is effective in blocking apoptosis in several different models, 
including anti-Fas induced cell death [36]. Despite this, anti-Fas did not induce CatD 
activity in the control cell line 4TO. To better understand the role of CatD in our cell 
model of NOS-3 overexpression, we analysed cell death-related parameters in the 
presence of pepstatin A. At 20μM, pepstatin A was able to inhibit CatD activity in 4TO-
NOS below the observed level in the control cell line 4TO. However, it did not affect 
the growth of 4TO or 4TO-NOS cells. As expected, 20μM pepstatin A failed to 
suppress the caspase-3 activity induced by anti-Fas in 4TO control cells, thus indicating 
that CatD activity is not essential for Fas-induced cell death in HepG2. These results 
differ from those previously published about the participation of the protease in 
apoptotic systems triggered by the activation of cell surface receptors [36,37]. On the 
other hand, CatD activity inhibition in 4TO-NOS caused a significant increase in the 
caspase-3 activity, which was significantly higher to that caused by the NOS-3 
overexpression at both in basal conditions and after anti-Fas addition. Thus, CatD 
activity induced by NOS-3 overexpression seemed to be associated with an anti-
apoptotic effect rather than pro-apoptotic. In this regard, it cannot be excluded an anti-
apoptotic role for CatD since it is overexpressed in many malignant tumors and it is 
associated with cancer spreading and clinical outcome, and its expression is conditional 
on apoptosis-associated protein phenotype [38]. Furthermore, the protease may promote 
cell survival under oxidative stress [39]. Despite of this, Beaujouin et al. reported that 
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CatD overexpression by cancer cells exerts a pro-apoptotic effect that is independent on 
its catalytic activity. Thus, cytosolic CatD would stimulate apoptosis by interacting with 
the apoptotic machinery rather than by cleaving specific substrates [40]. If so, we could 
not rule out a pro-apoptotic role for CatD in our cell model of NOS-3 overexpression 
since the CatD inhibitor pepstatin A stimulates the protease release from lysosomes at 
the commonly used dose of 50μM [41]. In such a scenario, the caspase-3 activity 
increase that we observed in 4TO-NOS after pepstatin A administration could be a 
consequence of a higher cytoplasmic localization of CatD, and not an effect caused by 
the CatD activity inhibition. This is consistent with the increased caspase-9 activity 
induced by pepstatin A in NOS-3 overexpressing cells, since inactive pro-caspase-9 is 
activated through the mitochondrial death pathway. Indeed, 50μM pepstatin A caused a 
significant slowing down of cell growth in 4TO-NOS. 
In conclusion, NOS-3 overexpression promoted AR and CatD up-regulation in a 
process related to oxidative stress generation and apoptosis induction. These 
observations agree with previous studies where both enzymes were associated with 
apoptosis, and were regulated by p53. Thus, AR and CatD emerge as new targets that 
could be involved in the reduction of cell survival in NOS-3 overexpressing cells, and 
join the list of proteins that we previously identified [14]. Overall, NOS-3 
overexpression caused a higher sensitivity to anti-Fas-induced cell death through the 
upregulation of pro-apoptotic genes and the increase in caspase-9 and caspase-3 
activities, without affecting AR and CatD activity and/or expression. Since the pro-
apoptotic effect of CatD overexpression may not be related to its enzymatic activity, we 
cannot exclude a significant role for this protein in the apoptosis induction by NOS-3 
overexpression. The potential role of the GAPDH increase in the regulation of p53 
activity in 4TO-NOS cells remains to be determined. Similarly, it remains to be 
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established the posttranslational modification affecting CatD activity during the NOS-3 
overexpression.  
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Figure Legends 
Figure 1. NOS-3 localization in 4TO-NOS cells. (A) Subcellular localization of NOS-
3 in 4TO-NOS. Effect of anti-Fas administration on the mitochondrial localization of 
NOS-3 (n=3). Densitometry of the lines corresponding to mitochondrial NOS-3 is 
shown. MTCO2 signal was used as loading control for cell lysate (CL), membrane 
fraction (MB) and mitochondrial fraction (MT). NOS-3 signal in cytoplasm (CYT) was 
referred to the protein load. (B) Mitochondrial localization of NOS-3 assessed by 
western blot. Mitochondrial fraction was subjected to enzymatic digestion with trypsin 
(6 or 20µg /100µg protein) or proteinase-K (PK, 10 or 40µg /100µg protein). (C) NOS-
3 cellular localization by confocal microscopy. Green: MTCO2 protein. Red: NOS-3 
protein. Blue: DAPI). Statistically significant differences between cell lines* or between 
treatments
# 
are marked. 
 
Figure 2. Oxidative phosphorylation system performance in 4TO-NOS cells. (A) 
Oxygen consumption of digitonin permeabilized cells in the presence of electron donors 
for complex I (Glutamate + Malate, G+M), complex II+III (Succinate + G3P, S+G3P), 
and complex IV (TMPD) (at basal condition: n=9; with anti-Fas: n=6 and n=8 for 4TO 
and 4TO-NOS cells, respectively; with L-NAME, n=3; with anti-Fas plus L-NAME, 
n=3). (B) Oxygen consumption rate in intact cells (at basal condition: n=5 and n=4 for 
4TO and 4TO-NOS, respectively; with anti-Fas: n=3). (C) Mitochondrial membrane 
potential (n=7). +L-NAME indicates treatment with anti-Fas plus L-NAME. Data are 
mean ± SEM. Statistically significant differences between cell lines* or between 
treatments
# 
are marked. 
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Figure 3. Effect of NOS-3 overexpression on the cellular nitro-oxidative status and 
mitochondrial biogenesis. (A) Quantification of protein nitration in the mitochondrial 
fraction by western blot (n=3). (B) Accumulation of nitric oxide end products, nitrates 
and nitrites, in the cell culture medium (n=3). (C) General ROS production was assessed 
by using probes DCF (n=11 for basal and anti-Fas; n=4 for L-NAME and +L-NAME) 
and DHE (n=8). (D) Gene expression analysis of antioxidant proteins GPX-1, GPX-4, 
Catalase, SOD-1, SOD-2 and GSS (n=4). (E) MtDNA copy number quantification 
(n=9). (F) Expression analysis of proteins from the mitochondrial respiratory complexes 
(n=3 or 4). B indicates basal conditions. +L-NAME (+L-N) indicates treatment with 
anti-Fas (A-F) plus L-NAME (L-N). Data are mean ± SEM. Statistically significant 
differences between cell lines* or between treatments
# 
are marked. 
 
Figure 4. Effect of anti-Fas administration on cell death. (A) Gene expression 
analysis of pro-apoptotic proteins APAF-1, BAX and BIK (n=4). (B) Cytoplasmic 
expression of cyt c. It is represented the cyt c/β-actin ratio versus the control cell line 
4TO at basal condition (n=3). (C) Caspase-9 and caspase-3-associated activities (n=4). 
Data are mean ± SEM. Statistically significant differences between cell lines* or 
between treatments
# 
are marked. 
 
Figure 5. Differentially expressed proteins in 4TO-NOS cells. (A) 2-D Master gel. 
Deregulated protein spots in 4TO-NOS are marked and numbered. (B) Western blot 
analysis of proteins 60 kDa heat shock protein mitochondrial (HSP60), protein 
disulfide-isomerase (PDI), thioredoxin-dependent peroxide reductase mitochondrial 
(PRDX3) and NADPH:adrenodoxin oxidoreductase mitochondrial (AR). A 
representative image of a Ponceau-stained membrane used in the western blot analysis 
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is shown. Data are mean ± SEM. Statistically significant differences between cell lines* 
or between treatments
# 
are marked. 
 
Figure 6. Cathepsin D activity and cell death. (A) CatD activity in cell lysates (n=4). 
(B) CatD activity inhibition curve by pepstatin A. Normal CatD activity in control cell 
line 4TO is marked. (C) Effect of 20μM pepstatin A on cell growth (n=3) and (D) 
caspase-3 (n=3) and (E) caspase-9 (n=3) activities. (F) Effect of 50μM pepstatin A on 
cell growth (n=4) and (G) caspase-3 activity (n=5) at 48h. +PA indicates treatment with 
pepstatin A (PA) plus anti-Fas. Data are mean ± SEM. Statistically significant 
differences between cell lines* or between treatments
# 
are marked. 
 
Figure 7. Cell death mechanisms in 4TO-NOS cells. NOS-3 overexpression was 
associated with cellular nitro-oxidative stress through the respiratory capacity increase 
of mitochondrial complex II+III and the tyrosine nitration of mitochondrial proteins. 
Nitro-oxidative stress induced by NOS-3 overexpression in HepG2 cells was related to 
1) the activation of the mitochondrial-associated caspase pathway through the 
expression increase of pro-apoptotic genes and the release of cyt c into the cytoplasm; 
2) the expression increase of proteins Adrenodoxin Reductase mitochondrial (AR) and 
Cathepsin D (CatD); and 3) higher susceptibility to anti-FAS induced cell death through 
activation of the apoptosis pathways. The expression regulation of these factors 
including Bax, Bik, Apaf-1, AR, CatD and FAS, has been previously related to p53, 
which is upregulated in 4TO-NOS cells. Both, ROS production and protein tyrosine-
nitration have been associated with p53 regulation and apoptosis. AR may contribute to 
oxidative stress. Pepstatin A (PA) induces apoptosis likely through the release of CatD 
from lysosomes. 
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Legend for Supplementary Figure 
Supplementary Figure 1. Representative 2-D gels for cell lines 4TO and 4TO-NOS. 
The effect of NOS-3 overexpression and anti-Fas administration was investigated. 
Differentially expressed proteins are marked and numbered according to Table 2. 
Figure 1
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Table 1. List of human primers used for RT-qPCR. 
Primer  Gene Position Sequence (5’ to 3’) 
GPx1-qF 
GPX1 
NM_000581.2 
301-320 TCGGCTTCCCGTGCAACCAG 
GPx1-qR 420-440 CGCACCGTTCACCTCGCACTT 
GPx4-qF 
GPX4 
NM_002085.3 
403-422 CCTTCCCGTGTAACCAGTTC 
GPx4-qR 587-609 ACTTGGTGAAGTTCCACTTGATG 
Cat-qF 
CAT 
NM_001752.3 
1028-1053 TGGTAAACTGGTCTTAAACCGGAATC 
Cat-qR 1159-1179 GGCGGTGAGTGTCAGGATAGG 
Sod1-qF 
SOD1 
NM_000454.4 
430-451 TGTGGCCGATGTGTCTATTGAA 
Sod1-qR 519-539 CACCTTTGCCCAAGTCATCTG 
Sod2-qF 
SOD2 
NM_001024465.1 
708-728 GGGAGCACGCTTACTACCTTC 
Sod2-qR 845-867 TCTTGCTGGGATCATTAGGGTAT 
GSS-qF GSS 
NM_000178.2 
286-308 AGATGGACTTCAACCTGCTAGTG 
GSS-qR 374-395 GTCAAAGAGACGAGCGGTAAAG 
Apaf1-qF 
APAF-1 
NM_ 013229.2 
3105-3128 TGGCAGTGGTTGCTTTGTCCCAGT 
Apaf1-qR 3190-3219 GGAGAAAACATCACACCATGAACCCAACTT 
Bax_qF BAX 
NM_138764.4 
229-251 GCGTCCACCAAGAAGCTGAGCGA 
Bax_qR 401-424 TGCTGGCAAAGTAGAAAAGGGCGA 
Bik-qF BIK 
NM_001197.4 
96-118 CTTGATGGAGACCCTCCTGTATG 
Bik-qR 166-186 AGGGTCCAGGTCCTCTTCAGA 
Rpl13A-qF 
RPL13A 
NM_012423.3 
541-563 CCTGGAGGAGAAGAGGAAAGAGA 
Rpl13A-qR 642-666 TTGAGGACCTCTGTGTATTTGTCAA 
 
GPX1, Glutathione peroxidase-1; GPX4, Glutathione peroxidase-4; Cat, Catalase; SOD-1, Cu/Zn-
Superoxide dismutase; SOD-2, Mn-Superoxide dismutase; GSS, Glutathione synthetase; APAF-1, 
apoptotic peptidase activating factor 1; BAX, BCL2-associated X protein; BIK, Bcl-2-interacting 
killer; RPL13A, Ribosomal protein L13A. Primers were designed using Primer3 software (v.0.4.0). 
 
 
Table 1
Table 2. Differentially expressed protein spots between cell lines 4TO and 4TO-NOS 
(NOS) identified by mass spectrometry. Differential expression ratio in bold indicates 
statistically significant expression with p<0.01. The rest with p<0.05. In the fold 
change box ‘NOS’ indicates ‘only expressed in 4TO-NOS’; + indicates anti-Fas 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2
 Protein name 
(Accession number) 
Molecular 
Function 
Spot 
Nº MS IS 
NOS  
vs.  
4TO  
NOS+ 
vs.  
4TO+  
4TO+ 
vs.  
4TO  
NOS+ 
vs.  
NOS 
M
e
ta
b
o
lis
m
 
Enoyl-CoA hydratase, mitochondrial (P30084) 
-oxidation 
46 589 470 1.3 1.7     
Medium-chain-specific acyl-CoA dehydrogenase 
mitochondrial (B7Z9I1) 27 379 290 5.4     -1.5 
Short/branched chain-specific acyl-CoA 
dehydrogenase mitochondrial (B4DQ51) 28 215 155 2.8   1.4   
GAPDH (P04406) Glycolysis 65 124 77 2.3   3.0   Alpha-enolase (P06733) 18 136 97       1.5 
D-3-phosphoglycerate dehydrogenase (O43175) Amino acids 8 269 157 -2.1 -1.8     
Retinal dehydrogenase 1 (P00352) Retinol 10 651 543 -3 -2.0   1.7 
Abhydrolase domain-containing protein14B 
(B4DQI4) Hydrolase 56 72 39 -2.5     2 
Sulfurtransferase (J3KPV7) Transferase 64 264 195 1.5     -1.5 
AMP deaminase 2 (Fragment) (H0Y360) IMP 104 48       5.2   
Adenylate kinase 2, mitochondrial (F8VY04) Energy 109 141 121     1.5   
R
N
A
 p
ro
c
e
s
s
in
g
 
hnRNPL (P14866) 
hnRNP/ 28S 
component 
4 132 111   -2.8     
5 206 173   -1.9     
hnRNPH (P31943) 12 674 569 -1.6       
hnRNPD0 (H0YA96) 24 273 229   -1.4     
hnRNPK (P61978) 50 360 314   -2.1     
28S RNPS22, mitochondrial (P82650) 63 278 185 2.6       
P
ro
te
in
 d
e
g
ra
d
a
ti
o
n
 
Cytosol aminopeptidase (P28838) 
Proteolysis 
/Protein 
stability 
11 573 417 -2.1 -2.0     
Aminoacylase-1 (Q03154) 25 135 79    2.6 -1.9   
Serine protease HTRA2, mitochondrial (O43464) 31 249 189    2.6     
Isochorismatase domain-containing protein 2, 
mitochondrial (Q96AB3) 73 264 217 3.7  2.3    
Cathepsin B (P07858) 37 288 204   1.4 1.8   54 407 332   -1.5 1.3   
Cathepsin D (P07339) 
41 498 389 NOS NOS+    
42 598 475 2.3 2.8    
44 268 223 1.9 2.1     
P
ro
te
in
 p
ro
c
e
s
s
in
g
 
60 kDa heat shock protein, mitochondrial 
(P10809) 
Chaperone 
/Protein 
assembly 
14 130 114   -4,1   -3.7 
15 415 350    -1.2 -1.5 
16 136   2.0 3,9     
17 287 210   -1,9     
78 kDa glucose-regulated protein (P11021) 
32 98 78    2,1     
48 513 434  -1,2   -1.3 
66 610 463  -1,8     
86 157 140 1.8     -1.4 
93 131 113   -1,5   -1.6 
Heat shock protein beta-1 (P04792) 47 300 255       1.8 
Protein DJ-1 (Q99497) 57 183 102   1,3     
GrpE protein homolog 1, mitochondrial (Q9HAV7) 58 313 271   2,5     
Stress-70 protein, mitochondrial (P38646) 68 441 386 1.8       
ATP synthase mitochondrial F1 complex 
assembly factor 1 (H0YD21) 38 70     8.4   3.1 
Calreticulin (P27797) 100 133 107   -1,5     
S
k
e
le
to
n
 
Actin, cytoplasmic 2 (P63261)   
  
26 761 614     1.7   
43 119 103  1.7     
Microtubule-actin cross-linking factor 1, isoforms 
1/2/3/5 (F5GZL7) 92 48 11   -2.6     
R
e
d
o
x
 H
o
m
e
o
s
ta
s
is
 
Thioredoxin (Fragment) (H7BZJ3) 
Oxido-
reductase 
/Isomerase 
36 148 128 1.4     -1.2 
Thioredoxin-dependent peroxide (E9PH29) 51 353 313 3.2 3.6     
NADPH:adrenodoxin oxidoreductase, 
mitochondrial (P22570) 55 582 506 3.7 3.1     
Peroxiredoxin-2 (P32119) 62 800 323 2.1 1.4 1.7   
Peroxiredoxin-1 (Q06830) 72 407 279     2.0   
SOD [Mn] mitochondrial (P04179) 74 450 375 3.2       
Aldo-keto reductase family 1 member C1 
(Q04828) 85 328 258 6.9 2.0 2.8   
Protein disulfide isomerase family A, member 3, 
isoformCRA_b (G5EA52) 
9 943 636   -5.1 3.7   
13 350 266   -2.1  -1.7 
67 406 299     1.9   
Protein disulfide-isomerase (H7BZ94) 30 196 149 -2.4       
Protein disulfide-isomerase (I3L2P8) 107   91 -2.4       
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